Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (DE:137)
FRANKFURT:137
Holding DE:137?
Track your performance easily
137 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.22 - €5.79
Previous Close€5.11
Volume0.00
Average Volume (3M)2.09K
Market Cap
€266.47M
Enterprise Value€201.66M
Total Cash (Recent Filing)$84.62M
Total Debt (Recent Filing)$15.61M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 02, 2024EPS Estimate
-€0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,549,598
10 Day Avg. Volume1,010
30 Day Avg. Volume2,088
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.71
Forecast
1Y Price Target
€10.35Price Target Upside129.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Announces Executive Team Changes
PremiumCompany Announcements
Aldeyra Therapeutics Announces Major Dry Eye Treatment Success
PremiumCompany Announcements
Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap
Options Prices
Currently, No data available
---
Ownership Overview
19.01% Insiders
11.31% Mutual Funds
3.51% Other Institutional Investors
56.10% Public Companies and
Individual Investors
137 FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was €2.22 and its highest was €5.79 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Currently, no data Available
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 02, 2024 which is 196 days ago.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -€0.076 earnings per share for the quarter, beating the consensus estimate of -€0.105 by €0.029.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -€0.11.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 59,549,600 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -€0.076 in its last earnings report, beating expectations of -€0.105. Following the earnings report the stock price went up 3.524%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Among the largest hedge funds holding Aldeyra Therapeutics’s share is Perceptive Advisors LLC. It holds Aldeyra Therapeutics’s shares valued at 31M.
---
Aldeyra Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.35 (129.12% Upside)
€10.35 (129.12% Upside)
Insider Transactions
Sold Shares
Worth $65.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.26%
12-Months-Change
Fundamentals
Return on Equity
-43.05%
Trailing 12-Months
Asset Growth
-20.34%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
137 Company Deck
---
137 Earnings Call
Q4 2023
0:00 / 0:00
---
137 Stock 12 Month Forecast
Average Price Target
€10.35
▲(129.12% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Atara Biotherapeutics
―
Corcept Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering 137
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+46.41%
reiterated a buy rating last month
Copying Justin Kim's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +46.41% per trade.
---